OBJECTIVE: To develop a blood-based test for screening populations at risk for Alzheimer disease. DESIGN: Case-control study. Subjects A total of 180 patients with mild cognitive impairment (MCI) and 105 age-matched, cognitively normal controls. INTERVENTIONS: The titer of beta-amyloid 1-42 autoantibodies in the plasma was obtained at the time of diagnosis and evaluated by enzyme-linked immunosorbent assay before and after dissociation of the antigen-antibody complexes. A total of 107 patients with MCI were followed up for 36 months; 70 of the 107 cases progressed to Alzheimer disease. RESULTS: The average level of beta-amyloid 1-42 plasma autoantibodies in patients with MCI that progressed to Alzheimer disease, but not that of the stable cases, was significantly higher than in cognitively normal controls (P < .001). CONCLUSIONS: The results suggest that the plasma beta-amyloid 1-42 autoantibodies parallel beta-amyloid 42 deposition in the brain, which is known to precede by several years the clinical onset of Alzheimer disease. The evaluation of beta-amyloid 1-42 autoantibodies after dissociation of the complexes is a simple and inexpensive method that can be used to predict the occurrence of Alzheimer disease.
OBJECTIVE: To develop a blood-based test for screening populations at risk for Alzheimer disease. DESIGN: Case-control study. Subjects A total of 180 patients with mild cognitive impairment (MCI) and 105 age-matched, cognitively normal controls. INTERVENTIONS: The titer of beta-amyloid 1-42 autoantibodies in the plasma was obtained at the time of diagnosis and evaluated by enzyme-linked immunosorbent assay before and after dissociation of the antigen-antibody complexes. A total of 107 patients with MCI were followed up for 36 months; 70 of the 107 cases progressed to Alzheimer disease. RESULTS: The average level of beta-amyloid 1-42 plasma autoantibodies in patients with MCI that progressed to Alzheimer disease, but not that of the stable cases, was significantly higher than in cognitively normal controls (P < .001). CONCLUSIONS: The results suggest that the plasma beta-amyloid 1-42 autoantibodies parallel beta-amyloid 42 deposition in the brain, which is known to precede by several years the clinical onset of Alzheimer disease. The evaluation of beta-amyloid 1-42 autoantibodies after dissociation of the complexes is a simple and inexpensive method that can be used to predict the occurrence of Alzheimer disease.
Authors: Andrea C Klaver; Mary P Coffey; Lynnae M Smith; David A Bennett; John M Finke; Loan Dang; David A Loeffler Journal: J Neuroinflammation Date: 2011-08-09 Impact factor: 8.322
Authors: Walter Maetzler; Anja Apel; Markus Langkamp; Christian Deuschle; Sarah Selina Dilger; Johannes Georg Stirnkorb; Claudia Schulte; Erwin Schleicher; Thomas Gasser; Daniela Berg Journal: PLoS One Date: 2014-02-21 Impact factor: 3.240
Authors: Fei Song; Anne Poljak; Nicole A Kochan; Mark Raftery; Henry Brodaty; George A Smythe; Perminder S Sachdev Journal: Proteome Sci Date: 2014-01-17 Impact factor: 2.480
Authors: Craig Ritchie; Nadja Smailagic; Anna H Noel-Storr; Yemisi Takwoingi; Leon Flicker; Sam E Mason; Rupert McShane Journal: Cochrane Database Syst Rev Date: 2014-06-10